Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Emicizumab binds to activated factor IX and factor X, reproducing the bridging function of the missing factor VIII. In a trial of emicizumab prophylaxis, emicizumab every 1 or 2 weeks led to a lower bleeding rate than no prophylaxis.

Bibliographische Detailangaben

Veröffentlicht in:	The New England journal of medicine 2018-08, Vol.379 (9), p.811-822
Hauptverfasser:	Mahlangu, Johnny, Oldenburg, Johannes, Paz-Priel, Ido, Negrier, Claude, Niggli, Markus, Mancuso, M. Elisa, Schmitt, Christophe, Jiménez-Yuste, Victor, Kempton, Christine, Dhalluin, Christophe, Callaghan, Michael U, Bujan, Willem, Shima, Midori, Adamkewicz, Joanne I, Asikanius, Elina, Levy, Gallia G, Kruse-Jarres, Rebecca
Format:	Artikel
Sprache:	eng
Schlagworte:	Bleeding Body weight Coagulation factors Factor VIII deficiency Fees & charges Hemophilia Hemostasis Monoclonal antibodies Pharmaceuticals Prophylaxis Thrombotic microangiopathy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!